STANFORD V REGIMEN OVER ABVD REGIMEN IN HODGKIN’S LYMPHOMA
Naga Manikanta Madduri*, Yash Pal, Sagarika Bandi and Margi Desai
ABSTRACT
Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system, particularly prevalent among young adults. In Hodgkin's lymphoma, treatment approaches have advanced, with both the ABVD regimen and the more intensive Standard V regimen serving as primary options. The Standard V regimen, noted for its dose-dense strategy, shows promise particularly for patients with advanced or high-risk disease, potentially achieving higher remission rates and extended progression-free survival. While ABVD remains favored for its proven effectiveness and manageable side effects, Standard V’s intensified approach increases hematologic toxicity, impacting patient quality of life. Deciding between these regimens often involves weighing efficacy against toxicity, tailored to each patient's condition.
[Full Text Article] [Download Certificate]